Current and emerging approaches for spine tumor treatment

B Costăchescu, AG Niculescu, BF Iliescu… - International Journal of …, 2022 - mdpi.com
Spine tumors represent a significant social and medical problem, affecting the quality of life
of thousands of patients and imposing a burden on healthcare systems worldwide …

Herbal compounds as promising therapeutic agents in precision medicine strategies for cancer: A systematic review

BA Tayeb, IY Kusuma, AAM Osman… - Journal of Integrative …, 2024 - Elsevier
Background The field of personalized medicine has gained increasing attention in cancer
care, with the aim of tailoring treatment strategies to individual patients for improved …

Sesquiterpene lactones as emerging biomolecules to cease cancer by targeting apoptosis

CY Hsu, S Rajabi, M Hamzeloo-Moghadam… - Frontiers in …, 2024 - frontiersin.org
Apoptosis is a programmed cell death comprising two signaling cascades including the
intrinsic and extrinsic pathways. This process has been shown to be involved in the therapy …

Gaillardin inhibits autophagy and induces apoptosis in MCF-7 breast cancer cells by regulating JAK/STAT pathway

S Rajabi, Z Tahmasvand, M Maresca… - Molecular Biology …, 2024 - Springer
Background Gaillardin is a potent anti-cancer sesquiterpene lactone found in Inula oculus-
christi. Aim The present study examined the effects of gaillardin on apoptosis and autophagy …

Natural products as potential drug treatments for acute promyelocytic leukemia

J Chen, Z Ding - Chinese Medicine, 2024 - Springer
Acute promyelocytic leukemia (APL), which was once considered one of the deadliest types
of leukemia, has become a curable malignancy since the introduction of all-trans retinoic …

Gaillardin exerts potent antileukemic effects on HL‐60 cells and intensifies arsenic trioxide cytotoxicity: Providing new insight into sesquiterpene lactones in leukaemia …

H Noormohamadi… - Clinical and …, 2024 - Wiley Online Library
The use of all‐trans retinoic acid and arsenic trioxide resulted in favourable therapeutic
responses in standard‐risk acute promyelocytic leukaemia (APL) patients. However …